Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
As of December 17, 2025, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is maintaining levels near its 52-week high, following peaks at $5.95 on December 12 and 13. The investor sentiment remains heightened as the company continues to advance the Rett syndrome program. Amid this strong share price momentum, The Fly reported that Goldman Sachs upgraded Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on December 4, 2025, to “Buy” from an Early-Stage Biotech designation. Setting an $11 price target, the bank expressed optimism around TSHA-102. The firm believes the company can achieve the 33% response rate, the minimum success threshold in the REVEAL study. The metric is a significant benchmark tied to regulatory progress. Corporate updates in the Q3 2025 results, announced on November 4, 2025, reinforced optimism. During the quarter, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) received FDA Breakthrough Therapy Designation for TSHA-102 for Rett syndrome. Furthermore, the company finalized alignm
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TSHA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.MarketBeat
TSHA
Earnings
- 11/4/25 - In-Line
TSHA
Sec Filings
- 12/1/25 - Form 4
- 11/28/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TSHA's page on the SEC website